- Home
- GLPG vs TSLX Comparison
GLPG vs TSLX Comparison
Compare GLPG & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- TSLX
- Stock Information
- Founded
- GLPG 1999
- TSLX 2010
- Country
- GLPG Belgium
- TSLX United States
- Employees
- GLPG N/A
- TSLX N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- TSLX Investment Managers
- Sector
- GLPG Health Care
- TSLX Finance
- Exchange
- GLPG Nasdaq
- TSLX Nasdaq
- Market Cap
- GLPG 2.1B
- TSLX 2.3B
- IPO Year
- GLPG 2005
- TSLX 2014
- Fundamental
- Price
- GLPG $32.02
- TSLX $24.66
- Analyst Decision
- GLPG Sell
- TSLX Buy
- Analyst Count
- GLPG 4
- TSLX 9
- Target Price
- GLPG $25.33
- TSLX $23.39
- AVG Volume (30 Days)
- GLPG 198.2K
- TSLX 331.1K
- Earning Date
- GLPG 10-29-2025
- TSLX 11-04-2025
- Dividend Yield
- GLPG N/A
- TSLX 8.39%
- EPS Growth
- GLPG N/A
- TSLX N/A
- EPS
- GLPG N/A
- TSLX 2.01
- Revenue
- GLPG $323,674,692.00
- TSLX $474,291,000.00
- Revenue This Year
- GLPG N/A
- TSLX N/A
- Revenue Next Year
- GLPG N/A
- TSLX N/A
- P/E Ratio
- GLPG N/A
- TSLX $12.30
- Revenue Growth
- GLPG 5.43
- TSLX 0.15
- 52 Week Low
- GLPG $22.36
- TSLX $18.58
- 52 Week High
- GLPG $33.86
- TSLX $25.17
- Technical
- Relative Strength Index (RSI)
- GLPG 49.28
- TSLX 58.13
- Support Level
- GLPG $30.88
- TSLX $24.37
- Resistance Level
- GLPG $33.63
- TSLX $24.79
- Average True Range (ATR)
- GLPG 0.69
- TSLX 0.26
- MACD
- GLPG -0.02
- TSLX 0.01
- Stochastic Oscillator
- GLPG 41.45
- TSLX 85.23
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.